Xcellerex 500 L and 2,000 L Bioreactors - GEN - Genetic Engineering and Biotechnology News
#Genetic Engineering#Bioreactors GEN#Genetic#GEN#Engineering
Life Science News
Latest updates from the biotech and pharma world
Cytiva and Asimov Collaborate on NextGen Cell Line Design and Process Development - GEN - Genetic Engineering and Biotechnology News
#Genetic Engineering#Asimov Collaborate#Cell Line#Line Design#Process Development
Decode DNA and Methylation Together with Illumina's 5 Base Solution | Interview with Fiona Kaper - Illumina
#Base Solution#Fiona Kaper#Decode DNA#Kaper Illumina#Illumina Decode
Cytiva develops two new protein A resins bringing cost efficiency to mAb capture - BioSpectrum India
#Cytiva develops#BioSpectrum India#resins bringing#bringing cost#cost efficiency
Roche, answering tariff threat, pledges $50B to US drug production - BioPharma Dive
Roche looks to expand and upgrade US research centers as part of $50B investment strategy in the country - Fierce Biotech
Roche to invest $50 billion in US to avoid Trump tariffs, create 12,000 jobs - Reuters
#Trump tariffs#avoid Trump#Reuters Roche#jobs Reuters#create
Roche follows peers with $50B investment in US manufacturing, research sites - FirstWord Pharma
#research sites#FirstWord Pharma#Pharma Roche#investment#manufacturing
Cytiva expands portfolio with new MabSelect Resins made from renewable agarose for scalable, cost-efficient mAb manufacturing - Express Pharma
#Express Pharma#MabSelect Resins#Resins made#cost-efficient mAb#Cytiva expands
Inside Lonza CHI’s Innovation Strategy: Future-Ready Capsules for Complex Drugs - PharmTech.com
#Innovation Strategy#Lonza CHI#Future-Ready Capsules#Complex Drugs#Inside Lonza
Unlocking the Potential of PROTACs in Drug Discovery - Technology Networks
#Drug Discovery#Technology Networks#Discovery Technology#Networks Unlocking#Potential
Illumina and Tempus partner to drive the future of precision medicine through genomic AI innovation - PR Newswire
#Tempus partner#precision medicine#Newswire Illumina#Tempus#Newswire
Ethris and Lonza focus on mRNA respiratory condition vaccines - Pharmaceutical Technology
#Pharmaceutical Technology#Lonza focus#mRNA respiratory#respiratory condition#Technology Ethris
Ethris and Lonza Collaborate to Develop Spray-Dried mRNA Vaccines for Respiratory Disease Prevention - BioSpace
#Lonza Collaborate#Respiratory Disease#Disease Prevention#Develop Spray-Dried#mRNA Vaccines
Ethris and Lonza Collaborate to Develop Spray-Dried mRNA Vaccines - Contract Pharma
#Lonza Collaborate#Contract Pharma#Develop Spray-Dried#mRNA Vaccines#Vaccines Contract
Ethris and Lonza Collaborate to Develop Spray-Dried mRNA Vaccines for Respiratory Disease Prevention - GEN - Genetic Engineering and Biotechnology News
#Genetic Engineering#Lonza Collaborate#Respiratory Disease#Disease Prevention#Develop Spray-Dried
Catching up with Lonza Capsules and Health Ingredients - Nutritional Outlook
#Lonza Capsules#Health Ingredients#Nutritional Outlook#Ingredients Nutritional#Outlook Catching
Lonza Investing in Large-Scale Biomanufacturing, Bioconjugation, Drug-Product Manufacturing - DCAT Value Chain Insights
#Large-Scale Biomanufacturing#Chain Insights#Drug-Product Manufacturing#Lonza Investing#Manufacturing DCAT
Cytiva expands MabSelect resin portfolio with new solutions for cost-effective and scalable mAb purification - BioSpectrum Asia
#Cytiva expands#BioSpectrum Asia#expands MabSelect#MabSelect resin#resin portfolio
SBTi validates Roche’s net-zero targets - Roche
#validates Roche#SBTi validates#net-zero targets#Roche SBTi#targets Roche